These agents have also been investigated prospectively for their effects on left ventricular ejection fraction (LVEF) as a surrogate of CV incidences with the objective of mitigating or reducing CV toxicities associated with anti-HER2 agents and anthracyclines in BC patients [23–33]. This evidence concerns the gene ERBB2 and breast cancer.